Modality
Peptide
MOA
MALT1i
Target
WRN
Pathway
JAK/STAT
DravetSCLC
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
~Feb 2018
→ ~May 2019
Phase 2
Aug 2019
→ Jun 2025
Phase 2Current
NCT05418629
369 pts·SCLC
2019-08→2025-06·Active
NCT06718549
106 pts·Dravet
2022-07→TBD·Recruiting
475 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-159mo agoPh3 Readout· SCLC
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-06-15 · 9mo ago
SCLC
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05418629 | Phase 2/3 | SCLC | Active | 369 | FEV1 |
| NCT06718549 | Phase 2/3 | Dravet | Recruiting | 106 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |